VRAX
Virax Biolabs Group Limited
NASDAQ · Healthcare · Biotechnology · GB
$2.63
+2.54%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 20.4K | 12.4K | 6.3K | 156.4K | 8.6K |
| Cost of Revenue | 281.2K | 4.7K | 59.4K | 105.8K | 9.9K |
| Gross Profit | (260.8K) | 7.7K | (53.1K) | 50.6K | (1.4K) |
| Operating Expenses | |||||
| R&D Expense | 6.9M | 3.7M | 1.8M | 1.6M | 397.1K |
| SG&A Expense | 8.0M | 2.7M | 4.3M | 4.6M | 5.3M |
| General & Admin Expense | 7.0M | 2.7M | 4.3M | 4.6M | 5.3M |
| Selling & Marketing Expense | — | — | — | — | 26.6K |
| Other Expenses | — | — | — | 390.4K | — |
| Total Operating Expenses | 14.9M | 6.4M | 6.1M | 6.5M | 5.7M |
| Cost and Expenses | 15.2M | 6.4M | 6.2M | 6.7M | 5.7M |
| Operating Income (EBIT) | (15.1M) | (6.4M) | (6.2M) | (6.5M) | (5.7M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 150.9K | 61.8K | 58.2K | 26.9K | 15.5K |
| Net Interest Income | (150.9K) | (61.8K) | (58.2K) | (26.9K) | (15.5K) |
| Other Non-Op Income/Expense | 394.9K | 467.3K | (41.0K) | (242.6K) | 275.0K |
| Non-Operating Income (excl Interest) | (528.7K) | (529.1K) | (17.2K) | 215.8K | (290.5K) |
| EBT (Pre-Tax Income) | (14.8M) | (5.9M) | (6.2M) | (6.7M) | (5.5M) |
| Income Tax Expense | (1.3M) | (900.2K) | (136.7K) | — | — |
| Bottom Line | |||||
| Net Income | (13.4M) | (5.0M) | (6.1M) | (6.7M) | (5.5M) |
| Earnings from Cont. Ops | (13.4M) | (5.0M) | (6.1M) | (6.7M) | (5.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (13.4M) | (5.0M) | (6.1M) | (6.7M) | (5.5M) |
| Per Share | |||||
| Basic EPS | ($66.14) | ($12.64) | ($49.00) | ($84.00) | ($128.25) |
| Diluted EPS | ($66.14) | ($12.64) | ($48.75) | ($84.00) | ($128.25) |
| Revenue Per Share | $0.05 | $0.03 | $0.05 | $1.95 | $0.20 |
| Shares | |||||
| Basic Shares Outstanding | 397590 | 397590 | 123884 | 80257 | 42519 |
| Diluted Shares Outstanding | 397590 | 397590 | 124142 | 80257 | 42519 |
| Profitability Metrics | |||||
| EBITDA | (13.8M) | (5.4M) | (5.8M) | (6.6M) | (5.4M) |
| D&A | 834.6K | 439.0K | 343.4K | 103.1K | 1.00 |
| EBIT | (14.6M) | (5.9M) | (6.1M) | (6.7M) | (5.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026